TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04628910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Flotation Therapy
Description: The Zerobody is a new technology designed to simulate the effects of traditional Float-REST therapy, but without the contact with salt water. The system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank. The system will be housed in a room that allows for significant reductions in light and sound to mimic the experience of a flotation tank. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks using the Zerobody, also termed dry floating, as one of the two interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Float-REST Therapy
Description: Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks as one of the two interventions.
Study: NCT02959606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate SR 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT04424680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Care Planning program of health decisions
Description: Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
Study: NCT04099420

Intervention type: BEHAVIORAL
Intervention: Lifestyle counseling
Description: An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students

Intervention type: BEHAVIORAL
Intervention: Lifestyle counseling
Description: An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
Study: NCT01170130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (sterile)
Description: during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
Study: NCT01076933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Stimulation Magnetic (rTMS)
Description: The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS
Study: NCT01405911

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sitagliptin 25 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sitagliptin 25 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sitagliptin 50 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sitagliptin 50 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study: NCT03695796

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank
Description: To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
Study: NCT03509584

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
Study: NCT03517436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR with CENTERA THV
Description: TAVR with the Edwards CENTERA THV System
Study: NCT03271710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral balloon angioplasty
Description: Percutaneous transluminal angioplasty (PTA) of the lower extremities
Study: NCT00109811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA:154-163(155L) peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02956655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting therapy
Description: The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)
Description: Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle guidance
Description: Lifestyle guidance is provided by specific physicians through phone calls

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle guidance
Description: Lifestyle guidance is provided by specific physicians through phone calls

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland
Study: NCT04032366

Intervention type: DRUG
Intervention: inhaled nitric oxide
Description: using of inhaled nitric oxide

Intervention type: DRUG
Intervention: inhaled nitric oxide
Description: using of inhaled nitric oxide

Intervention type: DEVICE
Intervention: PEEP
Description: increasing PEEP or decreasing PEEP

Intervention type: DEVICE
Intervention: PEEP
Description: increasing PEEP or decreasing PEEP
Study: NCT02594592

Intervention type: OTHER
Intervention: questionaire
Description: Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)

Intervention type: OTHER
Intervention: questionaire
Description: Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)

Intervention type: OTHER
Intervention: questionaire
Description: Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)

Intervention type: OTHER
Intervention: questionaire
Description: Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
Study: NCT04549012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin
Study: NCT00831051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: One morphine sulfate 12mg IR capsule q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl
Description: One oxycodone HCl 8mg IR Capsule q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: Two morphine sulfate 3mg IR capsules q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl 4mg
Description: Two oxycodone HCl 2mg IR Capsules q6h
Study: NCT02366819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study: NCT04322708

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study: NCT03597906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topography guided ablation
Description: using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
Study: NCT03325023

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and life style modification and probiotic Sanprobi Super Formula
Description: Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03505320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion.
Study: NCT03509584

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: administration of nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: administration of nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: administration of nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: administration of nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: administration of ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: administration of ipilimumab
Study: NCT02473744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subcutaneous drainage
Description: After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
Study: NCT02381327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandometer
Description: Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandometer
Description: Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
Study: NCT01028391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.
Description: Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.
Description: Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
Study: NCT03457584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: air arm
Description: epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BSS arm
Description: epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
Study: NCT00033345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol
Description: 400 mg pill taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol
Description: 800 mg pill taken daily
Study: NCT03597906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topography guided ablation
Description: using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topography guided ablation
Description: using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manifest refraction
Description: using for ablation the exact manifest refraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full topography modified refraction
Description: full topography modified refraction means changing both sphere and cylinder power in the ablation profile

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial topography modified refraction
Description: partial topography modified refraction means changing only cylinder power and axis in the ablation profile
Study: NCT00709592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO
Study: NCT03866551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Cardiovascular System
Description: The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
Study: NCT00921921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Description: HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
Study: NCT00746538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent
Description: Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
Study: NCT03400293

Intervention type: OTHER
Intervention: Functional Assessment of HIV Infection
Description: Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.

Intervention type: OTHER
Intervention: Patient Satisfaction Questionnaire
Description: Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.

Intervention type: OTHER
Intervention: Symptom Distress Module
Description: Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.

Intervention type: OTHER
Intervention: Patient Health Questionnaire
Description: Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.

Intervention type: OTHER
Intervention: Internalized Stigma of AIDS Tool
Description: Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.

Intervention type: OTHER
Intervention: Medication adherence visual analogue scale
Description: Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
Study: NCT00553787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 15 mg and topiramate 92 mg, po once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 7.5 mg and topiramate 46 mg, po once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VI-0521
Description: placebo
Study: NCT02039154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and strength training group
Description: A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and flexibility group
Description: For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
Study: NCT03927040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MemorEM 1000
Description: The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.